Associated with novel therapies in patients with multiple Myeloma: Consensus statement of the IMF nurse leadership board

Clinical Journal of Oncology Nursing

Volumn 12, Issue SUPPL. 3, 2008, Pages 21-28

  Rome, Sandra ^a   Doss, Deborah ^b   Miller, Kena ^c   Westphal, Jeanne ^d  

^a Cedar Sinai Medical Center   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Cancer Institute   (United States)

^d Meeker County Memorial Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CHEMICALLY INDUCED DISORDER; CONSENSUS; HUMAN; LEADERSHIP; MULTIPLE MYELOMA; NURSING ORGANIZATION; PATIENT EDUCATION; RISK FACTOR; THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS; CONSENSUS; HUMANS; LEADERSHIP; MULTIPLE MYELOMA; PATIENT EDUCATION AS TOPIC; RISK FACTORS; SOCIETIES, NURSING; THROMBOEMBOLISM;

EID: 49649097943     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/08.CJON.S1.21-27     Document Type: Article

References (50)

1. Austin, H., Key, N.S., Benson, J.M., Lally, C., Dowling, N.F., Whitsett, C., et al. (2007). Sickle cell trait and the risk of venous thromboembolism among blacks. Blood, 110(3), 908-912.
2. Barlogie, B., Tricot, G., Rasmussen, E., Anaissie, E., van Rhee, F., Zangari, M., et al. (2005). Total therapy 3 (TT3) incorporating Velcade® (V) into upfront management of multiple myeloma (MM): Comparison with TT2 + thalidomide (T) [Abstract 1154].Blood, 106, 1154.
3. Bauer, K.A. (2001). The thrombophilias: Well-defined risk factors with uncertain therapeutic implications. Annals of InternalMedicine, 135(5), 367-373.
4. Baxter Healthcare. (2004). Heparin sodium injection, USP [Package insert]. Deerfield, IL: Author.
5. Bennett, C.L., Angelotta, C., Yarnold, P.R., Evens, A.M., Zonder, J.A., Raisch, D.W., et al. (2007). Thalidomide- and lenalidomideassociated thromboembolism among patients with cancer. JAMA, 296(2), 2558-2560.
6. Bennett, C.L., Hussain, Z., Courtney, M., Yarnold, P., Raisch, D., & McKoy, J.M. (2006). RADAR update on thalidomide (Thal) - and lenalidomide (Len)-associated venous thromboembolism (VTE): Safety concerns persist for multiple myeloma (MM) despite FDA approvals in this setting [Abstract 3310]. Blood, 108, 3310.
7. Bertolotti, P., Bilotti, E., Colson, K., Curran, K., Doss, D., Faiman, B., et al. (2007). Nursing guidelines for enhanced patient care. Haematologica, 92(Suppl. 2), 211.
8. Bertolotti, P., Bilotti, E., Colson, K., Curran, K., Doss, D., Faiman, B., et al. (2008). Management of side effects of novel therapies for multiple myeloma: Consensus statements developed by the International Myeloma Foundation's Nurse Leadership Board. Clinical Journal of Oncology Nursing, 12(3, Suppl.), 9-12.
9. Bristol-Myers Squibb. (2007). Coumadin® (warfarin sodium) anticoagulant [Package insert]. Princeton, NJ: Author.
10. Caprini, J.A. (2006). Venous thromboembolism risk factor assessment. Retrieved October 22, 2007, from https://www.med.umich.edu/clinical/images/VTE-Risk-Assessment.pdf
11. Celgene Corporation. (2007a). Revlimid® (lenalidomide) [Package insert]. Summit, NJ: Author.
12. Celgene Corporation. (2007b). Thalomid® (thalidomide) [Package insert]. Summit, NJ: Author.
13. Coalition to Prevent Deep-Vein Thrombrosis. (2006). Are you at risk for a DVT blood clot? Retrieved September 18, 2007, from https://www.preventdvt.org/docs/pdf/DVTRiskAssessment Tool
14. Durie, B.G., Richardson, P., Palumbo, A., Dimopoulos, M.A., Cavo, M., Hajek, R., et al. (2006). Deep vein thrombosis in myeloma: Estimate of prevalence and recommendations for therapy based upon a survey of members of the International Myeloma WorkingGroup (IMWG) [Abstract 3751]. Blood, 108, 3571.
15. Ghobrial, J., Ghobrial, I.M., Mitsiades, C., Leleu, X., Hatjiharissi, E., Moreau, A.S., et al. (2007). Novel therapeutic avenues in myeloma:Changing the treatment paradigm. Oncology, 21(7), 785-792.
16. Glaxo SmithKline. (2005). Arixtra® (fondaparinux sodium) [Package insert]. Research Triangle Park, NC: Author.
17. Handin, R.I. (2005). Bleeding and thrombosis. In D.L. Kasper, A.S. Fauci, D.L. Longo, E. Baunwald, S.L. Hauser, J.L. Jameson, et al. (Eds.), Harrison's principles of internal medicine (16th ed., pp 1-24). New York: McGraw-Hill.
18. Harousseau, J.L., Jagannath, S., Richardson, P.G., Sonneveld, P., Schuster, M.W., Esseltine, D.L., et al. (2006). Bortezomib in combination with high-dose dexamethasone (HD dex) and erythropoietin (EPO) does not result in an increased risk of thromboembolic complications [Abstract]. Blood, 108, 3543.
19. Heit, J.A., O'Fallon, W.M., Petterson, T.M., Lohse, C.M., Silverstein, M.D., Mohr, D.N., et al. (2002). Relative impact of risk factors for deep vein thrombosis and pulmonary embolism. A population-based study. Archives of Internal Medicine, 162(11), 1245-1248.
20. Heit, J.A., Silverstein, M.D., Mohr, D.N., Petterson, T.M., O'Fallon, W.M., & Melton, J. (2000). Risk factors for deep vein thrombosisand pulmonary embolism. A population-based case-control study.Archives of Internal Medicine, 160(6), 809-815.
21. Hussein, M. (2006). Thromboembolism risk reduction in multiplemyeloma patients treated with immunomodulatory combinations. Thrombosis and Haemostasis, 95(6), 924-930.
22. Joffe, H.V., Kucher, N., Tapson, V.F., & Goldhaber, S.Z. (2004). Upper-extremity deep vein thrombosis: A prospective registry of 592 patients. Circulation, 110(12), 1605-1611.
23. Khorana, A.A., Francis, C.W., Culakova, E., Fisher, R.I., Kuderer, N.M., & Lyman, G.H. (2006). Thromboembolism in hospitalizedneutropenic cancer patients. Journal of Clinical Oncology, 24(3), 484-490.
24. Knight, R., DeLap, R.J., & Zeldis, J.B. (2006). Lenalidomide andvenous thrombosis in multiple myeloma. New England Journalof Medicine, 354(19), 2079-2080.
25. Lonial, S., Richardson, P.G., San Miguel, J., Sonneveld, P., Schuster, M., Blade, J., et al. (2007). Hematologic profiles with bortezomib in relapsed MM. Haematologica, 92(Suppl. 2), 159-160.Retrieved April 10, 2008, from http://www.haematologica.it/content/vol92/6_supplement_2/index.dtl.
26. Manochakian, R., Miller, K.C., & Chanan-Khan, A.A. (2007). Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma. Oncologist, 12(8), 978-990.
27. Millennium Pharmaceuticals, Inc. (2007). Velcade® (bortezomib) [Package insert]. Cambridge, MA: Author.
28. Miller, K., Padmanabhan, S., Dimicelli, L., Depaolo, D., Landrigan, B., Yu, J., et al. (2006). Prospective evaluation of low-dose warfarinfor prevention of thalidomide associated venous thromboembolism. Leukemia and Lymphoma, 47(11), 2339-2343.
29. National Cancer Institute. (2006). Common Terminology Criteria for Adverse Events v.3.0. Retrieved August 8, 2007, from http://ctep.cancer.gov/forms/CTCAEv3.pdf
30. National Comprehensive Cancer Network. (2007). NCCN Clinical Practice Guidelines in Oncology™: Venous thromboembolic disease [v.1.2007]. Retrieved September 10, 2007, from http://www.nccn.org/professionals/physician_gls/PDF/vte.pdf
31. Offidani, M., Corvatta, L., Marconi, M., Visani, G., Alesiani, F., Brunori, M., et al. (2005). Thalidomide, dexamethasone and pegylated-liposomal doxorubicin (ThaDD) for untreated multiple myeloma patients aged over 65 years [Abstract 2558]. Blood, 106, 2558.
32. Ortho Biotech Products, L.P. (2007). Doxil® (doxorubicin HCl liposome injection) [Package insert]. Bridgewater, NJ: Author.
33. Otten, H.M., Mathijssen, J., ten Cate, H., Soesan, M., Inghels, M., Richel, D.J., et al. (2004). Symptomatic venous thromboembolism in cancer patients treated with chemotherapy. Archives of Internal Medicine, 164(2), 190-194.
34. Palumbo, A., Rajkumar, S.V., Dimopoulos, M.A., Richardson, P.G., San Miguel, J., Barlogie, B., et al. (2008). Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma. Leukemia, 22(2), 414-423.
35. Pfizer, Inc. (2007). Fragmin® (dalteparin sodium injection) [Prescribing information]. New York: Author.
36. Prandoni, P. (2005). Acquired risk factors for venous thromboembolism in medical patients. Hematology, 1, 458-461.
37. Prandoni, P., Falanga, A., & Piccioli, A. (2005). Cancer and venous thromboembolism. Lancet Oncology, 6(6), 401-410.
38. Qaseem, A., Snow, V., Barry, P., Hornbake, E.R., Rodnick, J.E., Tobolic, T., et al. (2007). Current diagnosis of venous thromboembolismin primary care: A clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Annals of Family Medicine, 5(1), 57-62.
39. Rajkumar, S.V., & Gertz, M.A. (2006). Response (to Zonder et al., Blood 2006): Lenalidomide therapy and deep-vein thrombosis in multiple myeloma [Letter to the editor]. Blood, 108, 404.
40. Rajkumar, S.V., Hayman, S.R., Lacy, M.Q., Dispenzieri, A., Geyer, S.M., Kabat, B., et al. (2005). Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood, 106(13), 4050-4053.
41. Richardson, P.G., & Anderson, K. (2006). Thalidomide and dexamethasone: A new standard of care for initial therapy in multiple myeloma. Journal of Clinical Oncology, 24(3), 334-335.
42. Richardson, P.G., Hideshima, T., Mitsiades, C., & Anderson, K.C. (2007). The emerging role of novel therapies for the treatment of relapsed myeloma. Journal of the National Comprehensive Cancer Network, 5(2), 149-162.
43. Richardson, P.G., Jagannath, S., Avigan, D.E., Alsina, M., Schlossman, R.L., Mazumder, A., et al. (2006). Lenalidomide plus bortezomib(Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): Final results of a multicenter phase 1 trial [Abstract 405]. Blood, 108, 405.
44. sanofi-aventis. (2007). Lovenox® (enoxaparin sodium injection) [Package insert]. Bridgewater, NJ: Author.
45. Spencer, F.A., Lessard, D., Emery, C., Reed, G., & Goldberg, R.J. (2007). Venous thromboembolism in the outpatient setting. Archives of Internal Medicine, 167(14), 1471-1475.
46. Story, K.T. (2006). Deep venous thrombosis. In D. Camp-Sorrell, & R.A. Hawkins (Eds.), Clinical manual for the oncology advanced practice nurse. (2nd ed., pp. 281-290). Pittsburgh, PA: Oncology Nursing Society.
47. Van Gerpen, R., & Mast, M.E. (2004). Thromboembolic disorders in cancer. Clinical Journal of Oncology Nursing, 8(3), 289-299.
48. Viale, P.H., & Schwartz, R.N. (2004). Venous thromboembolism in patients with cancer. Part I. Survey of oncology nurses' attitudesand treatment practices for ambulatory settings. Clinical Journal of Oncology Nursing, 8(5), 455-461.
49. Zangari, M., Siegal, E., Barlogie, B., Anaissie, E., Saghafifar, F., Fassas, A., et al. (2002). Thrombogenic activity of doxorubicin in myelomapatients receiving thalidomide: Implications for therapy. Blood, 100(4), 1168-1171.
50. Zonder, J.A., Barlogie, B., Durie, B.G.M., McCoy, J., Crowley, J., & Hussein, M.A. (2006). Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: Benefit of aspirin prophylaxis. Blood, 108(1), 403.